Early intervention of atopic dermatitis as a preventive strategy for progression of food allergy.

Atopic dermatitis Ceramides Eczema Emollients Filaggrin Food allergy Prevention Skin barrier Stratum corneum Trilipids

Journal

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
ISSN: 1710-1484
Titre abrégé: Allergy Asthma Clin Immunol
Pays: England
ID NLM: 101244313

Informations de publication

Date de publication:
16 Mar 2021
Historique:
received: 01 10 2020
accepted: 20 02 2021
entrez: 17 3 2021
pubmed: 18 3 2021
medline: 18 3 2021
Statut: epublish

Résumé

Atopic diseases, such as atopic dermatitis (AD) and food allergy (FA), have increased in prevalence in industrialized countries during the past few decades and pose a significant health burden. They appear to have a common underlying mechanism and a natural disease progression. AD is generally the first atopic disease to manifest followed by other atopic diseases, such as FA, allergic rhinitis, or allergic asthma suggesting that they are likely different manifestations of the same disease. BODY: Evidence suggests that allergic sensitization occurs through an impaired skin barrier, while consumption of these foods at an early age may actually result in tolerance. This has been termed the Dual-Allergen-Exposure hypothesis. Loss of barrier integrity has been hypothesized to enable penetration of allergens, pollutants, and microbes and initiation of an inflammatory immune cascade of events leading to sensitization. The immune dysfunction is thought to further exacerbate the impaired skin barrier to form a vicious cycle. There is much interest in preventing or protecting the skin barrier from developing a proinflammatory atopic state, which may potentially lead to the development of AD and subsequently, FA. Research on preventing or treating skin barrier dysfunction is ongoing. A number of studies have evaluated the efficacy of emollients in preventing AD and FA with mixed results. Studies have differed in the study design, population characteristics, emollients type, and frequency, duration, and area of application. Emollient type has varied widely from oils, creams, petrolatum-based lotions, and trilipid creams. Current research is directed towards the use of trilipid emollients that are similar to the skin's natural lipid composition with a 3:1:1 ratio of ceramides, cholesterol and free fatty acids and a pH that is similar to that of skin to determine their effectiveness for skin barrier repair and prevention of AD and FA.

Sections du résumé

BACKGROUND BACKGROUND
Atopic diseases, such as atopic dermatitis (AD) and food allergy (FA), have increased in prevalence in industrialized countries during the past few decades and pose a significant health burden. They appear to have a common underlying mechanism and a natural disease progression. AD is generally the first atopic disease to manifest followed by other atopic diseases, such as FA, allergic rhinitis, or allergic asthma suggesting that they are likely different manifestations of the same disease. BODY: Evidence suggests that allergic sensitization occurs through an impaired skin barrier, while consumption of these foods at an early age may actually result in tolerance. This has been termed the Dual-Allergen-Exposure hypothesis. Loss of barrier integrity has been hypothesized to enable penetration of allergens, pollutants, and microbes and initiation of an inflammatory immune cascade of events leading to sensitization. The immune dysfunction is thought to further exacerbate the impaired skin barrier to form a vicious cycle. There is much interest in preventing or protecting the skin barrier from developing a proinflammatory atopic state, which may potentially lead to the development of AD and subsequently, FA.
CONCLUSION CONCLUSIONS
Research on preventing or treating skin barrier dysfunction is ongoing. A number of studies have evaluated the efficacy of emollients in preventing AD and FA with mixed results. Studies have differed in the study design, population characteristics, emollients type, and frequency, duration, and area of application. Emollient type has varied widely from oils, creams, petrolatum-based lotions, and trilipid creams. Current research is directed towards the use of trilipid emollients that are similar to the skin's natural lipid composition with a 3:1:1 ratio of ceramides, cholesterol and free fatty acids and a pH that is similar to that of skin to determine their effectiveness for skin barrier repair and prevention of AD and FA.

Identifiants

pubmed: 33726824
doi: 10.1186/s13223-021-00531-8
pii: 10.1186/s13223-021-00531-8
pmc: PMC7962338
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

30

Références

Immunity. 2015 Jul 21;43(1):29-40
pubmed: 26200011
J Clin Invest. 1998 Apr 15;101(8):1614-22
pubmed: 9541491
J Allergy Clin Immunol. 2019 Dec;144(6):1615-1623
pubmed: 31812185
J Allergy Clin Immunol. 2015 Apr;135(4):930-935.e1
pubmed: 25618747
N Engl J Med. 2011 Oct 6;365(14):1315-27
pubmed: 21991953
Curr Opin Immunol. 2020 Oct;66:14-21
pubmed: 32299014
Lancet. 2020 Mar 21;395(10228):962-972
pubmed: 32087126
Skin Pharmacol Physiol. 2006;19(6):296-302
pubmed: 16864974
Ann Allergy Asthma Immunol. 2018 Feb;120(2):131-137
pubmed: 29413336
JAMA Pediatr. 2013 Nov;167(11):1026-31
pubmed: 24042236
N Engl J Med. 2016 May 5;374(18):1733-43
pubmed: 26943128
Environ Res. 2018 Jan;160:462-468
pubmed: 29078139
J Allergy Clin Immunol Pract. 2019 Feb;7(2):345-355.e2
pubmed: 30717865
J Allergy Clin Immunol. 2016 Apr;137(4):1111-1116.e8
pubmed: 26924469
Dermatology. 2019;235(5):355-364
pubmed: 31203284
JAMA Pediatr. 2018 Jun 4;172(6):e180315
pubmed: 29610864
Ann Allergy Asthma Immunol. 2018 Feb;120(2):145-151
pubmed: 29413338
Pediatrics. 2019 Mar;143(3):
pubmed: 30819972
J Allergy Clin Immunol. 2010 Dec;126(6 Suppl):S1-58
pubmed: 21134576
Lancet. 2020 Mar 21;395(10228):951-961
pubmed: 32087121
Pediatrics. 2003 Jun;111(6 Pt 3):1662-71
pubmed: 12777607
J Invest Dermatol. 2009 Aug;129(8):1892-908
pubmed: 19494826
J Allergy Clin Immunol. 2015 Jan;135(1):164-70
pubmed: 25457149
Br J Dermatol. 2019 Mar;180(3):464-474
pubmed: 29969827
Eur J Nutr. 2018 May;57(Suppl 1):1-14
pubmed: 29748817
J Allergy Clin Immunol. 2014 Oct;134(4):824-830.e6
pubmed: 25282564
J Allergy Clin Immunol Pract. 2013 Jan;1(1):22-8
pubmed: 24229818
Curr Allergy Asthma Rep. 2020 Feb 14;20(2):6
pubmed: 32067114
J Allergy Clin Immunol. 2018 Jan;141(1):41-58
pubmed: 29157945
J Allergy Clin Immunol. 2014 Oct;134(4):867-875.e1
pubmed: 25282568
J Allergy Clin Immunol Pract. 2018 Jul - Aug;6(4):1342-1348
pubmed: 29174063
J Pediatr. 2000 Dec;137(6):749-55
pubmed: 11113829
Korean J Pediatr. 2017 May;60(5):145-150
pubmed: 28592977
Clin Exp Allergy. 2015 Jan;45(1):255-64
pubmed: 25210971
Allergy Asthma Immunol Res. 2020 Jan;12(1):137-148
pubmed: 31743970
Ann Allergy Asthma Immunol. 2018 Sep;121(3):313-319
pubmed: 29909054
Br J Dermatol. 2010 Dec;163(6):1333-6
pubmed: 21137118
N Engl J Med. 2015 Feb 26;372(9):803-13
pubmed: 25705822
J Allergy Clin Immunol. 2013 Sep;132(3):630-638
pubmed: 23608730
Int Arch Allergy Immunol. 2019;180(3):202-211
pubmed: 31394530
Dermatol Clin. 2017 Jul;35(3):283-289
pubmed: 28577797
J Invest Dermatol. 1996 May;106(5):1096-101
pubmed: 8618046
Adv Exp Med Biol. 2020;1253:107-140
pubmed: 32445093
Int Arch Allergy Immunol. 2019;179(3):187-191
pubmed: 30943491
J Dermatol. 2018 Jan;45(1):24-30
pubmed: 28983938
Pediatr Allergy Immunol. 2018 Aug;29(5):538-544
pubmed: 29663520
J Allergy Clin Immunol. 2001 Feb;107(2):367-74
pubmed: 11174206
Br J Dermatol. 2018 Jan;178(1):e19-e21
pubmed: 28639306
Pediatr Allergy Immunol. 2020 Nov;31(8):938-945
pubmed: 32585042
G Ital Dermatol Venereol. 2020 Feb;155(1):19-23
pubmed: 31525844
Arch Dermatol. 1995 Jul;131(7):809-16
pubmed: 7611797
N Engl J Med. 2003 Mar 13;348(11):977-85
pubmed: 12637607
J Eur Acad Dermatol Venereol. 2019 Nov;33(11):2087-2094
pubmed: 31287580
Allergy. 2014 Jan;69(1):17-27
pubmed: 24117677
J Allergy Clin Immunol. 2019 Dec;144(6):1606-1614.e2
pubmed: 31812184
J Allergy Clin Immunol. 2014 Oct;134(4):818-23
pubmed: 25282563
Expert Rev Clin Immunol. 2019 Aug;15(8):889-896
pubmed: 31305181
Environ Health. 2020 Jan 14;19(1):6
pubmed: 31937319
Nat Rev Dis Primers. 2018 Jun 21;4(1):1
pubmed: 29930242

Auteurs

Alyssa Sweeney (A)

Sean N. Parker Center for Allergy and Asthma Research at Stanford University, 240 Pasteur Dr. BMI Rm.1755, Palo Alto, CA, 94304, USA.
Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Stanford University, Stanford, CA, 94305, USA.

Vanitha Sampath (V)

Sean N. Parker Center for Allergy and Asthma Research at Stanford University, 240 Pasteur Dr. BMI Rm.1755, Palo Alto, CA, 94304, USA.
Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Stanford University, Stanford, CA, 94305, USA.

Kari C Nadeau (KC)

Sean N. Parker Center for Allergy and Asthma Research at Stanford University, 240 Pasteur Dr. BMI Rm.1755, Palo Alto, CA, 94304, USA. knadeau@stanford.edu.
Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Stanford University, Stanford, CA, 94305, USA. knadeau@stanford.edu.

Classifications MeSH